Prophylactic and therapeutic treatment with acyclovir of genital herpes in the guinea pig.
The antiviral drug, acyclovir, was tested on experimentally infected guinea pigs with either of two herpes simplex virus type 1 (HSV-1) isolates following intravaginal inoculation. The drug was continuously infused subcutaneously utilizing an osmotic pump. Infusion was begun either prior to virus inoculation (prophylactic) or after virus inoculation at the time of first appearance of lesions (therapeutic). Prophylactic treatment markedly reduced the severity of the genital lesions, the appearance of acute neurologic sequellae, and the virus excretion in the genital tract of guinea pigs infected with either of the two strains tested. Therapeutic acyclovir treatment, however, did not decrease the incidence of acute neurologic sequellae with one of the two HSV-1 strains tested, nor did it reduce the severity of the genital lesions of either strain. These neurologic sequellae may be due to insufficient levels of ACV in the central nervous system as the concentration of ACV in the dorsal root ganglia was found to exceed that of the plasma, but only trace amounts of acyclovir were present in the brain and spinal cord. Continuous perfusion of ACV gave far higher tissue levels than intermittent injections. These findings suggest that prophylactic ACV is far more effective than therapeutic treatment for genital herpes in the guinea pig model.
D000212:Acyclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D005260:Female; D005836:Genitalia, Female / Q000382:microbiology; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D009422:Nervous System Diseases / Q000209:etiology; D010477:Perfusion; D018139:Simplexvirus / Q000302:isolation & purification; D013997:Time Factors; D014018:Tissue Distribution
D000212:Acyclovir